)
Visual
test
OncoZenge
OncoZenge (ONCOZ) investor relations material
OncoZenge Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary30 Oct, 2025
Executive summary
Secured SEK 46.7 million in funding for the European Phase III trial of BupiZenge™, including investments from Yangtian Bio-Pharmaceutical, milestone payments from Molteni Farmaceutici, and a convertible note from Linc AB.
Manufacturing and site selection for the Phase III trial are underway, with first patient enrollment expected in Q2 2026.
Strategic partnerships established with Molteni Farmaceutici (Europe) and Avernus Pharma (GCC region) for commercialization.
Strengthened sponsor team and operational readiness for the pivotal trial, including collaborations with Meribel Pharma and LINK Medical.
Financial highlights
Q3 2025 net sales: SEK 0 thousand (Q3 2024: 0); operating result: SEK -3,479 thousand (Q3 2024: -1,755); EPS: SEK -0.28 (Q3 2024: -0.15).
Jan–Sep 2025 net sales: SEK 2,664 thousand (Jan–Sep 2024: 0); operating result: SEK -6,040 thousand (Jan–Sep 2024: -6,184); EPS: SEK -0.51 (Jan–Sep 2024: -0.53).
Cash flow for Jan–Sep 2025: SEK 7,727 thousand (Jan–Sep 2024: -6,797); cash and cash equivalents at Sep 30, 2025: SEK 11,590 thousand.
Equity ratio at Sep 30, 2025: 46.90% (Dec 31, 2024: 87.02%).
Outlook and guidance
Fully funded to initiate and execute the European Phase III trial, with first patient enrollment targeted for Q2 2026.
Remaining investment tranches from Yangtian Bio-Pharmaceutical expected in Q4 2025 and Q1 2026.
Anticipates milestone payment from Molteni Farmaceutici upon EMA trial application approval, not earlier than March 2026.
Ongoing business development for China and US market entry, and label expansion opportunities.
FDA toxicology study impact on US market entry
Molteni milestone repayment risk
Prioritize BupiZenge label expansion beyond OM
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next OncoZenge earnings date
Q4 202518 Feb, 2026
OncoZenge
Next OncoZenge earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. Its products include Palonosetron Fertiginject, an antiemetic product developed and launched in the Nordics; and Yserenate, a pharmaceutical preparation that is used for the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency, as well as for the treatment of hypophosphatemia in patients with chronic kidney disease. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage